Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene

被引：0
|
作者：
RJ O'Connell
VR Polonis
S Ratto-Kim
J Cox
LL Jagodzinski
J Malia
NL Michael
J Excler
ML Robb
JH Kim
机构：
[1] U.S.Military HIV Research Program,
[2] International AIDS Vaccine Initiative,undefined
来源：
Retrovirology | / 9卷
关键词：
Primary Isolate; Vaccine Recipient; Chromium Release; Adjuvanting Strategy; Boost Regimen;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 11 条
  • [1] Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene
    O'Connell, R. J.
    Polonis, V. R.
    Ratto-Kim, S.
    Cox, J.
    Jagodzinski, L. L.
    Malia, J.
    Michael, N. L.
    Excler, J.
    Robb, M. L.
    Kim, J. H.
    RETROVIROLOGY, 2012, 9
  • [2] Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene
    O'Connell, Robert J.
    Excler, Jean-Louis
    Polonis, Victoria R.
    Ratto-Kim, Silvia
    Cox, Josephine
    Jagodzinski, Linda L.
    Liu, Michelle
    Wieczorek, Lindsay
    McNeil, John G.
    El-Habib, Raphaelle
    Michael, Nelson L.
    Gilliam, Bruce L.
    Paris, Robert
    VanCott, Thomas C.
    Tomaras, Georgia D.
    Birx, Deborah L.
    Robb, Merlin L.
    Kim, Jerome H.
    JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (12): : 1946 - 1954
  • [3] Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants
    Frey, Sharon E.
    Peiperl, Laurence
    McElrath, M. Juliana
    Kalams, Spyros
    Goepfert, Paul A.
    Keefer, Michael C.
    Baden, Lindsey R.
    Lally, Michelle A.
    Mayer, Kenneth
    Blattner, William A.
    Harro, Clayton D.
    Hammer, Scott M.
    Gorse, Geoffrey J.
    Hural, John
    Tomaras, Georgia D.
    Levy, Yves
    Gilbert, Peter
    deCamp, Allan
    Russell, Nina D.
    Elizaga, Marnie
    Allen, Mary
    Corey, Lawrence
    CLINICAL AND VACCINE IMMUNOLOGY, 2014, 21 (11) : 1589 - 1599
  • [4] Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial
    Moodie, Zoe
    Andersen-Nissen, Erica
    Grunenberg, Nicole
    Dintwe, One B.
    Omar, Faatima Laher
    Kee, Jia J.
    Bekker, Linda-Gail
    Laher, Fatima
    Naicker, Nivashnee
    Jani, Ilesh
    Mgodi, Nyaradzo M.
    Hunidzarira, Portia
    Sebe, Modulakgota
    Miner, Maurine D.
    Polakowski, Laura
    Ramirez, Shelly
    Nebergall, Michelle
    Takuva, Simbarashe
    Sikhosana, Lerato
    Heptinstall, Jack
    Seaton, Kelly E.
    De Rosa, Stephen
    Diazgranados, Carlos A.
    Koutsoukos, Marguerite
    van der Meeren, Olivier
    Barnett, Susan W.
    Kanesa-thasan, Niranjan
    Kublin, James G.
    Tomaras, Georgia D.
    Mcelrath, M. Juliana
    Corey, Lawrence
    Mngadi, Kathryn
    Goepfert, Paul
    PLOS MEDICINE, 2024, 21 (03)
  • [5] Comparison between Env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults
    Ratto-Kim, S
    Loomis-Price, LD
    Aronson, N
    Grimes, J
    Hill, C
    Williams, C
    El Habib, R
    Birx, DL
    Kim, JH
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (01) : 9 - 17
  • [6] A phase 112 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (Subtype E) candidate vaccine - ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivolent gp120 (CM235/SF2) boost
    Thongcharoen, Prasert
    Suriyanon, Vinai
    Paris, Robert M.
    Khamboonruang, Chirasak
    de Souza, Mark S.
    Ratto-Kim, Silvia
    Karnasuta, Chitraporn
    Polonis, Victoria R.
    Baglyos, Lynn
    El Habib, Raphaelle
    Gurunathan, Sanjay
    Barnett, Susan
    Brown, Arthur E.
    Birx, Deborah L.
    McNeil, John G.
    Kim, Jerome H.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (01) : 48 - 55
  • [7] Safety and Reactogenicity of ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Prime-Boost Vaccination Regimen in a Community-Based Efficacy Trial
    Pitisuttithum, P.
    Rerks-Ngarm, S.
    Bussaratid, V.
    Dhitavat, J.
    Maekanantawat, W.
    Pungpak, S.
    Suntharasamai, P.
    Vanijanonta, S.
    Nitayapan, S.
    Kaewkungwal, J.
    Chunsuttiwat, S.
    Premsri, N.
    Benenson, M.
    Morgan, P.
    Berenberg, J.
    Gurunathan, S.
    Francis, D. P.
    Chiu, J.
    Excler, J.
    Robb, M. L.
    Stablein, D.
    Michael, N. L.
    Kim, J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : A74 - A74
  • [8] Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160(MN) (ALVAC-HIV): A double-blind controlled randomized study of safety and immunogenicity
    Tubiana, R
    Gomard, E
    Fleury, H
    Gougeon, ML
    Mouthon, B
    Picolet, H
    Katlama, C
    AIDS, 1997, 11 (06) : 819 - 820
  • [9] Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160
    Lee, D
    Graham, BS
    Chiu, YL
    Gilbert, PB
    McElrath, MJ
    Belshe, RB
    Buchbinder, SP
    Sheppard, HW
    Koblin, BA
    Mayer, KH
    Keefer, MC
    Mulligan, MJ
    Celum, CL
    JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (05): : 903 - 907
  • [10] Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection
    Salmon-Céron, D
    Excler, JL
    Finkielsztein, L
    Autran, B
    Gluckman, JC
    Sicard, D
    Matthews, TJ
    Meignier, B
    Valentin, C
    El Habib, R
    Blondeau, C
    Raux, M
    Moog, C
    Tartaglia, J
    Chong, P
    Klein, M
    Milcamps, B
    Heshmati, F
    Plotkin, S
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (07) : 633 - 645
12